Platelet derived growth factor receptor antagonist - BeyondSpring Pharmaceutical

Drug Profile

Platelet derived growth factor receptor antagonist - BeyondSpring Pharmaceutical

Alternative Names: MTLH 001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wuxi MTLH Biotechnology
  • Developer BeyondSpring Pharmaceuticals; Shanghai Pharmaceutical Group
  • Class Antineoplastics; Peptides
  • Mechanism of Action Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in China
  • 07 Jan 2016 Preclinical trials in Cancer in USA (unspecified route) before January 2016
  • 07 Jan 2016 BeyondSpring Pharmaceutical plans to file an IND application for Cancer in USA in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top